ReviewDiagnostics (Basel, Switzerland)2022
Combinatorial Power of cfDNA, CTCs and EVs in Oncology.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- Robotic Centrifugal Microfluidics with In-Rotation Liquid Supply for the Extraction of Multiple Liquid Biopsy Analytes in One Platform.Biosensors · 2026Article
- Review
- Biomimetic Membrane Interface Technologies for Detection and Isolation of CTCs and EVs: Advances and Opportunities in Liquid Biopsy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.BMC cancer · 2025Article
- Potentialities and challenges of liquid biopsy in clinical cancer management.Biomarkers in medicine · 2025Review
- GUIDE: a prospective cohort study for blood-based early detection of gastrointestinal cancers using targeted DNA methylation and fragmentomics sequencing.Molecular cancer · 2025Observational
- On the dilemma of using single EV analysis for liquid biopsy: the challenge of low abundance of tumor EVs in blood.Theranostics · 2025Review
- Improvement of the sensitivity of circulating tumor DNA-based liquid biopsy: current approaches and future perspectives.Exploration of targeted anti-tumor therapy · 2025Review
- Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.Cancer science · 2024Review
- The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins.International journal of molecular sciences · 2024Review
- Circulating tumor cellsTranslational breast cancer research : a journal focusing on translational research in breast cancer · 2024Review
- The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- Review
- Cell-Free Nucleic Acids: Physico-Chemical Properties, Analytical Considerations, and Clinical Applications.Diagnostics (Basel, Switzerland) · 2023Article
- Characteristics of Extracellular Vesicles from a High-Grade Serous Ovarian Cancer Cell Line Derived from a Platinum-Resistant Patient as a Potential Tool for Aiding the Prediction of Responses to Chemotherapy.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Evaluating tumor cell- and T cell-derived extracellular vesicles as potential biomarkers of cancer and immune cell competence.Expert review of molecular diagnostics · 2023Article
- New Perspectives on the Importance of Cell-Free DNA Biology.Diagnostics (Basel, Switzerland) · 2022Review
- Preanalytical Variables in the Analysis of Mitochondrial DNA in Whole Blood and Plasma from Pancreatic Cancer Patients.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy is a promising technique for clinical management of oncological patients. The diversity of analytes circulating in the blood useable for liquid biopsy testing is enormous. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and extracellular vesicles (EVs), as well as blood cells and other soluble components in the plasma, were shown as liquid biopsy analytes. A few studies directly comparing two liquid biopsy analytes showed a benefit of one analyte over the other, while most authors concluded the benefit of the additional analyte. Only three years ago, the first studies to examine the value of a characterization of more than two liquid biopsy analytes from the same sample were conducted. We attempt to reflect on the recent development of multimodal liquid biopsy testing in this review. Although the analytes and clinical purposes of the published multimodal studies differed significantly, the additive value of the analytes was concluded in almost all projects. Thus, the blood components, as liquid biopsy reservoirs, are complementary rather than competitive, and orthogonal data sets were even shown to harbor synergistic effects. The unmistakable potential of multimodal liquid biopsy testing, however, is dampened by its clinical utility, which is yet to be proven, the lack of methodical standardization and insufficiently mature reimbursement, logistics and data handling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.